Global

Home to some of the world’s most important international health institutions and some big pharma players as well, Switzerland lays claim as a healthcare and life sciences powerhouse. Navigating its pharmaceutical market terrain, however, does not come without its challenges.

The external reference pricing circus has rolled back into town, promising another great European show. The fight-back comes via one of Europe's most obscure bodies, the European Integrated Price Information Database-better known as Euripid.

The Innovation Scorecard was developed to track compliance with NICE Technology Appraisals. Leela Barham reviews its latest update.

Nine months on from the 2016 EFPIA Disclosure Code deadline - requiring all member companies across Europe to publish their data concerning their transfer-of-value transactions to HCPs - EFPIA's Andrew Powrie-Smith offered an update on media and industry responses.

The EMA released the revised Module V- Risk Management Systems (Rev 2) of Good Pharmacovigilance Practice (GVP) (EMA/838713/2011 Rev 2) accompanied by a revised Guidance on the format of the risk management plan (RMP) in the EU.

It is hard to resist the sensation that the rhetoric of Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.

A conversation with Tommy Fanning, head of biopharma at IDA Ireland, about the country’s growth as a manufacturing powerhouse-and its bid to attract UK-based EMA post-Brexit.

Is the Greek pharmaceuticals and healthcare sector, once a strong bridge between Europe and the East, on the mend after suffering the recent ravages of the global financial crisis and subsequent austerity policies?

March 28, 2017

March 28, 2017

March 27, 2017

March 24, 2017

March 20, 2017